Status:
COMPLETED
Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate \< 20% and a worse tolerability of the t...
Eligibility Criteria
Inclusion
- Metastatic melanoma (stage III non operable or stage IV according to American Joint Committee on Cancer staging rules) refractory to immunotherapy (≥ 2nd treatment line after minimum a failure of immunotherapy)
Exclusion
- Uveal melanoma
Key Trial Info
Start Date :
March 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06586580
Start Date
March 30 2023
End Date
December 31 2023
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Besançon
Besançon, France